According to the latest report by IMARC Group, titled “Vaccine Market Report by Technology (Conjugate Vaccines, Inactivated and Subunit Vaccines, Live Attenuated Vaccines, Recombinant Vaccines, Toxoid Vaccines, and Others), Patient Type (Pediatric, Adult), Indication (Bacterial Diseases, Viral Diseases), Route of Administration (Intramuscular and Subcutaneous Administration, Oral Administration, and Others), Product Type (Multivalent Vaccine, Monovalent Vaccine), Treatment Type (Preventive Vaccine, Therapeutic Vaccine), End User (Hospitals, Clinics, Vaccination Centers, Academic and Research Institutes, and Others), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Institutional Sales, and Others), and Region 2025-2033”, offers a comprehensive analysis of the industry, which comprises insights on the global vaccine market size. The report also includes competitor and regional analysis, and contemporary advancements in the global market.
The global vaccine market size reached USD 59.8 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 136.5 Billion by 2033, exhibiting a growth rate (CAGR) of 9.12% during 2025-2033.
Global Vaccine Market Dynamics:
Increasing Prevalence of Infectious Diseases:
The persistent and new risks of infectious diseases is what drives the global vaccine market. The new and older herd of viral and bacterial infections along with increased population density, necessitate effective plans for immunization. Respiratory infections including, but not limited to, seasonal flu, measles and pneumonia can be mitigated with public health vaccinations from government and non-profit organizations, which also expand the impact of the market. Futhermore, the growing antibiotic resistance significantly increases the dependencies on preventative measures where the facilities of vaccines are mandatory.
Technological Advancements and Innovation:
Innovation in technology is one of the factors propelling demand in the vaccine industry. New developments in biology, genomics and immunology such as mRNA, viral vector and subunit vaccines make it easier to develop vaccine products. These tools have shorter development time, better safety and more powerful action against infection-causing agents. In addition, new tools for administering vaccines, like microneedle patches and intranasal sprays, are more convenient and encourage patients to comply. The constant work on improvement of vaccine methods is essential to counter new infectious diseases and enhance the health of the world population.
Growing Geriatric Population and Chronic Diseases:
The growth in the market for vaccines is influenced by the rising global elderly demographic and chronic disease cases. There is a considerable need for vaccines for illnesses such as influenza, pneumonic pneumonia, and shingles because older adults, who are among the more vulnerable members of society due to underlying chronic illnesses, are at an increased risk for infectious diseases. Additionally, the growing rates of chronic illnesses, including numerous cancers and autoimmune diseases, is contributing towards the use of immunotherapeutic vaccines to specifically treat and alter the immune system. This combination of changes in demographic features and the problems related to ensuring public health creates a widening scope for the use of vaccines which propels the growth of the market.
Request Free Sample Report: https://www.imarcgroup.com/vaccine-market/requestsample
Global Vaccine Market Trends:
There are remarkable trends at the same time in the global vaccine market. Focus on personalized and precise vaccination is one of the most significant trend. The developments in genomics and immunoprobing are allowing for the creation of vaccines based on a person’s genetic makeup and immune response. This approach will improve the effectiveness of vaccines and reduce the side effects offered.
Another important trend is the heightened attention being paid to preparedness and rapid response services for pandemics. These crises have underscored the need to build strong health systems. Investments in vaccine supply ecommerce coupled with scalable manufacturing technologies and simplified regulatory procedures are essential to ensure these vaccines can be quickly accessed in times of outbreaks. In addition, there are growing public-private partnerships to accelerate vaccine innovation and strengthen global health protection.
By the IMARC Group, Some of the Top Competitive Landscape Operating in the Vaccine Market Report are Given Below:
- Abbott Laboratories
- Astellas Pharma Inc.
- AstraZeneca Plc
- Bharat Biotech International
- Bavarian Nordic A/S
- CSL Limited
- Daiichi Sankyo Company Limited
- Emergent BioSolutions Inc.
- GlaxoSmithKline Plc
- Inovio Pharmaceuticals Inc.
- Johnson & Johnson
- Merck & Co. Inc.
- Mitsubishi Tanabe Pharma Corporation (Mitsubishi Chemical Holdings Corporation)
- Novavax Inc.
- Panacea Biotec Ltd.
- Pfizer Inc.
- Sanofi Pasteur SA (Sanofi SA)
- Serum Institute of India Pvt. Ltd.
- Takeda Pharmaceutical Company Limited.
Explore the Full Report with Charts, Table of Contents, and List of Figures: https://www.imarcgroup.com/vaccine-market
Key Market Segmentation:
Breakup by Technology:
- Conjugate Vaccines
- Inactivated and Subunit Vaccines
- Live Attenuated Vaccines
- Recombinant Vaccines
- Toxoid Vaccines
- Others
Breakup by Patient Type:
- Pediatric
- Adult
Pediatric patients hold the largest share of the market
Breakup by Indication:
- Bacterial Diseases
- Meningococcal Disease
- Pneumococcal Disease
- Diphtheria/Tetanus/Pertussis (DPT)
- Tuberculosis
- Haemophilus Influenzae (Hib)
- Typhoid
- Others
- Viral Diseases
- Hepatitis
- Influenza
- Human Papillomavirus (HPV)
- Measles/Mumps/Rubella (MMR)
- Rotavirus
- Herpes Zoster
- Varicella
- Japanese Encephalitis
- Rubella
- Polio
- Rabies
- Dengue
- Others
Bacterial diseases presently account for the largest market share
Breakup by Route of Administration:
- Intramuscular and Subcutaneous Administration
- Oral Administration
- Others
Intramuscular and subcutaneous administration represents the leading segment
Breakup by Product Type:
- Multivalent Vaccine
- Monovalent Vaccine
Multivalent vaccine represent the most used product type
Breakup by Treatment Type:
- Preventive Vaccine
- Therapeutic Vaccine
Preventive vaccine currently dominates the market
Breakup by End User:
- Hospitals
- Clinics
- Vaccination Centers
- Academic and Research Institutes
- Others
Hospitals hold the largest share of the market
Breakup by Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Institutional Sales
- Others
Hospital pharmacies presently account for the largest market share
Regional Insights:
- North America (United States, Canada)
- Asia Pacific (China, Japan, India, Australia, Indonesia, Korea, Others)
- Europe (Germany, France, United Kingdom, Italy, Spain, Others)
- Latin America (Brazil, Mexico, Others)
- Middle East and Africa (United Arab Emirates, Saudi Arabia, Qatar, Iraq, Other)
Asia Pacific exhibits a clear dominance in the market
Key highlights of the Report:
- Market Performance
- Market Outlook
- COVID-19 Impact on the Market
- Porter’s Five Forces Analysis
- Historical, Current and Future Market Trends
- Market Drivers and Success Factors
- SWOT Analysis
- Structure of the Market
- Value Chain Analysis
- Comprehensive Mapping of the Competitive Landscape
Note: If you need specific information that is not currently within the scope of the report, we can provide it to you as a part of the customization.
About Us
IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.
IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.
Contact US:
IMARC Group
134 N 4th St. Brooklyn, NY 11249, USA
Email: sales@imarcgroup.com
Tel No:(D) +91 120 433 0800
United States: +1-631-791-1145
Comments
0 comment